Navigation Links
MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
Date:9/11/2008

GAITHERSBURG, Md. and TOKYO, Sept. 11 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., announced today that they have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. MedImmune has global rights to any resulting product candidates and will be responsible for preclinical and clinical development, as well as all future development, manufacturing, sales and marketing activities.

"It's an honor to work with Ken-ichi Arai, founder of SBI Biotech and one of Japan's leading scientists. We look forward to collaborating with him and his organization as we develop potential new treatments for autoimmune diseases such as SLE," said Anthony J. Coyle, Ph.D., vice president, research, respiratory, inflammation and autoimmunity. "As an innovative company dedicated to making a difference for patients, MedImmune will continue to seek out research and development initiatives that may address some of society's critical unmet medical needs."

Under the terms of the agreement, MedImmune is to provide SBI Biotech with an undisclosed upfront payment, milestone payments and royalties on future marketed products. SBI Biotech has granted MedImmune an exclusive license to research, develop and commercialize products that target the ILT7 protein. In addition, MedImmune will have the option to license additional targets resulting from SBI Biotech's research activities.

"We are pleased to collaborate with MedImmune, a company with strong capabilities to develop therapeutic antibodies including expertise in humanization and large-scale production. MedImmune is an excellent company and this agreement facilitates the research and development of an anti-ILT7 antibody," said Ken-ichi Arai, M.D. and Ph.D., president & CEO, SBI Biotech. "We have been seeking other potential targets for treatments of autoimmune diseases and cancer and will continue further research and development. We are confident that the collaboration with MedImmune will greatly strengthen the potential for our program."

About ILT7

ILT7 is a cell surface protein uniquely expressed on plasmacytoid dendritic cells (pDC). Targeting ILT7 offers potential to treat autoimmune diseases because pDCs are believed to be critical in the development of autoimmune diseases such as systemic lupus erythematosus.

About MedImmune

MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune's website at http://www.medimmune.com.

About SBI Biotech Co., Ltd.

SBI Biotech Co., Ltd, the drug subsidiary company of SBI Holdings, Inc. is conducting its business as the global bioventure company by assembling discovery pipelines from Japan, United States, China and Korea. SBI Biotech advances drug discovery and new therapy by utilizing the global network of SBI researchers, receiving investments from venture capital and by collaborating with pharmaceutical companies and university hospitals. For more information on SBI Biotech, please refer to the company's website at http://www.sbibiotech.jp.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
2. MedImmune Expands Scientific and Engineering Leadership
3. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
4. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
5. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
6. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
7. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
8. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
9. Further Acquisition for Schofield Media Group LLC
10. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
11. Area Women Gather in Milford on July 10 to Further the Mission of Womens Caring Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
Breaking Medicine Technology: